Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

• Main Authors: Isla D (Author), De Castro J (Author), Juan O (Author), Grau S (Author), Orofino J (Author), Gordo R (Author), Rubio-Terrés C (Author), Rubio-Rodríguez D (Author)
• Formato: Livro
• Publicado em: Dove Medical Press, 2016-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza, 2Medical Oncology Department, Universitary Hospital La Paz, Madrid, 3Medical...